Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-02-11Clinical Trial Update: Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel [Phase 2]
A Phase 2 trial of cabazitaxel plus buparlisib for metastatic castration-resistant prostate cancer previously treated with docetaxel has bee…
-
CLINICAL_TRIALS withdrawal · 2016-02-11Clinical Trial Update: Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide [NA]
A clinical trial evaluating an exercise intervention for patients with metastatic castration-resistant prostate cancer receiving abiraterone…
-
CLINICAL_TRIALS trial_result · 2016-02-08Clinical Trial Update: Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program [NA]
A completed clinical trial update evaluating TaRgets in Genito Urinary Screening Program for metastatic castration-resistant prostate cancer…
-
FDA approval · 2016-01-22FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for XOFIGO (radium Ra-223 dichloride) from Bayer HealthCare Pharmaceuticals, updating its labeling/i…
-
CLINICAL_TRIALS trial_result · 2015-12-14Clinical Trial Update: EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer [Phase 2]
Phase 2 study of EMD 525797 in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer has completed and results …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2015-12-10FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA granted a supplemental application for ZYTIGA (abiraterone acetate) to update its labeling, expanding or modifying its approved indi…
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
A post-marketing surveillance study evaluating the safety and effectiveness of abiraterone acetate in adult Filipino men with advanced metas…
-
CLINICAL_TRIALS withdrawal · 2015-11-20Clinical Trial Update: A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 trial evaluating the combination of radium-223 dichloride with tasquinimod for bone-only metastatic castration-resistant prostate …
-
FDA approval · 2015-11-06FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental NDA for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., to update the labeling and/or expand an ind…
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [NA]
Continuation study of sunitinib malate for patients who left a prior sunitinib trial; completed with results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study evaluating the combination of cabazitaxel and abiraterone acetate in patie…
-
CLINICAL_TRIALS trial_result · 2015-11-02Clinical Trial Update: A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer [Phase 2]
Phase 2 study evaluating novel scheduling of cabazitaxel for metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-30Clinical Trial Update: Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer [Phase 2]
A Phase 2 clinical trial investigating exogenous testosterone plus dutasteride for metastatic castration-resistant prostate cancer has compl…
-
CLINICAL_TRIALS withdrawal · 2015-10-27Clinical Trial Update: A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer [Phase 1]
A Phase 1b dose-escalation study of PSK with docetaxel for metastatic castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-10-21Clinical Trial Update: A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer [Phase 3]
Phase 3 study of tasquinimod in men with metastatic castration-resistant prostate cancer has completed.
-
FDA approval · 2015-10-01FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc., reflecting an updated indication/la…
-
CLINICAL_TRIALS withdrawal · 2015-09-01Clinical Trial Update: STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling [Phase 2]
Phase 2 study of STA-9090 (ganetespib) in castration-resistant prostate cancer was withdrawn. The trial included assessment of androgen rece…
-
CLINICAL_TRIALS trial_result · 2015-08-13Clinical Trial Update: Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity
A completed clinical trial evaluating whether lean body mass influences the pharmacokinetics and toxicity of docetaxel. The study involved p…
-
FDA approval · 2015-08-05FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc. The approval expands the labelin…
-
CLINICAL_TRIALS trial_result · 2015-07-20Clinical Trial Update: Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC [Phase 1]
Phase 1 clinical trial update for GEN0101 in patients with recurrent castration-resistant prostate cancer; the trial status is currently unk…
-
CLINICAL_TRIALS research · 2015-06-25Clinical Trial Update: Analysis of the Mechanisms of Actions of Heat Shock Protein (Hsp27) Responsible of the Androgen-independent Evolution in Prostate Cancer [NA]
Sponsored by Institut Paoli-Calmettes, this trial analyzed how Heat Shock Protein 27 contributes to the evolution of prostate cancer to an a…
-
CLINICAL_TRIALS trial_result · 2015-06-24Clinical Trial Update: Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer [Phase 1, Phase 2]
This is an update on a Phase 1-2 trial of onapristone in patients with advanced castration-resistant prostate cancer, with the current statu…
-
CLINICAL_TRIALS trial_result · 2015-06-23Clinical Trial Update: Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update reporting safety and efficacy results for pertuzumab in castration-resistant prostate cancer.
-
FDA approval · 2015-06-18FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA supplemental approval for JEVTANA (cabazitaxel) by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2015-06-11FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for JEVTANA (cabazitaxel) from Sanofi-Aventis U.S. LLC.